Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients.

Metastatic Colorectal Cancer Clinical Trial

— BECOX  

Official title:

A Non Randomized Phase II Trial to Assess Efficacy and Safety of Bevacizumab, Capecitabine and Oxaliplatin as First Line Treatment for Elderly Patients With Metastatic Colorectal Adenocarcinoma, Suitable for Polychemotherapy Treatment

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01067053
• Other study ID #: GEMCAD-0901
• Status: Active, not recruiting
• Phase: Phase 2
• First received: January 21, 2010
• Last updated: January 8, 2014
• Start date: November 2009
• Est. completion date: March 2014

Study information

• Verified date: January 2014
• Source: Grupo Espanol Multidisciplinario del Cancer Digestivo
• Contact: n/a
• Is FDA regulated: No
• Health authority: Spain: Spanish Agency of Medicines
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether bevacizumab, capecitabine and oxaliplatin are an effective and safe first line of treatment for elderly patients with metastatic colorectal adenocarcinoma.

Description:

The efficacy will be determined by objective response rate following RECIST criteria.

In several clinical trials with Bevacizumab, there has been demonstrated that elderly patients benefits as well as the younger of a combination therapy with chemotherapy plus Bevacizumab, but these results have come from subgroup analyses of trials not specifically design to test the effect of these combinations on the elderly. This clinical trial is specific only for elderly patients and we expect to confirm the benefits demonstrated in other clinical trials where the elderly patients were a number reduced.

This clinical trial includes 3 substudies:

• Assessment of tumor response of CRC liver metastases to treatment with Avastin in combination with Capecitabine and Oxaliplatin as first line treatment by dynamic ultrasound contrast.

Main objective: Assess the performance of dynamic contrast ultrasonography (CEUS, Contrast Enhanced UltraSound) with quantification of tumor perfusion in the evaluation of tumor response of liver metastases of colorectal carcinoma to treatment with Avastin in combination with Capecitabine and Oxaliplatin.

-Evaluation of the antiangiogenic activity of bevacizumab combined with oxaliplatin and capecitabine in first line treatment using MDCT perfusion studies in liver metastases of colorectal cancer in patients over 70 years.

Main objective:Determine whether the observed changes in perfusion CT studies performed at 2 weeks of starting treatment compared to baseline are significant predictors of free time to disease progression in patients in the trial and defined as the time since the start of treatment until objective progressive disease by RECIST criteria.

-Characterization of resistance to bevacizumab in colon cancer in elderly patients.

Main objective: To evaluate the involvement of serum markers and markers in the primary tumor in the resistance to bevacizumab.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 69
• Est. completion date: March 2014
• Est. primary completion date: November 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 70 Years and older

Eligibility

Inclusion Criteria:

• Written informed consent.

• ECOG 0-1.

• Age = 70 years.

• Histologically confirmed carcinoma of the colon and/or rectum.

• Metastatic disease non suitable for radical surgery.

• At least one measurable metastatic lesion (as per RECIST criteria). The index lesion must not be in a previously irradiated area.

• Non prior chemotherapy for metastatic disease. Adjuvant (or neo-adjuvant for rectal cancer patients) chemotherapy allowed if completed = 12 months before inclusion.

• Life expectancy more than 3 months.

• Adequate renal function: creatinine = 1.5 x UL and calculated creatinine clearance = 30 mL/min.

• Adequate level function: AST and ALT = 2.5 x UL (= 5 x UL if liver metastases), bilirubin = 1.5 x UL.

• Adequate haematological function: Hb = 9 gr/dl, neutrophils = 1,5 x 109 /l and platelets = 100000 x 109/l.

• Urine dipstick for proteinuria < 2+. If urine dipstick is = 2+, 24 hour urine must demonstrate = 1 g of protein in 24 hours.

• No clinical evidence or history of metastatic CNS disease.

• No prior Bevacizumab treatment.

Exclusion Criteria:

• Patients who previously received bevacizumab.

• Prior chemotherapeutic treatment for metastatic CRC.

• Prior treatment with monoclonal antibodies.

• Clinical evidence of brain metastases or history or evidence upon physical examination of CNS disease unless adequately treated.

• Past or current history (within the last 5 years prior to treatment start) of other malignancies except metastatic colorectal cancer (Patients with curatively treated basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible).

• Clinically significant cardiovascular disease, for example CVA (= 6 months before treatment start), myocardial infarction (= 6 months before treatment start), unstable angina, NYHA = grade 2, CHF, arrhythmia requiring medication, or uncontrolled hypertension.

• Intestinal occlusion/subocclusion.

• Chronic diarrhea.

• Treatment with any other investigational agent, or participation in another clinical trial within 30 days prior to entering this study.

• Known hypersensitivity to any of the study drugs.

• Current or recent (within 10 days of first dose of study treatment) daily use of aspirin (> 325 mg/day) or other NSAID.

• Current or recent (within 10 days prior to study treatment start) use of full-dose oral or parenteral anticoagulants or thrombolytic agent for therapeutic (as opposed to prophylactic) purposes. Patients receiving (or considered candidate to receive) anticoagulants agents as prophylaxis of cardiovascular risk, should continue (or start) the appropriate treatment at study entry.

• History of venous thromboembolic or haemorrhagic events within 6 months prior to treatment.

• Patients with previous of arterial thromboembolic event.

• Evidence of bleeding diathesis or coagulopathy.

• Serious, non healing wound, ulcer, or bone fracture.

• Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to treatment, or anticipation of the need for major surgery during the course of the study.

• Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment-related complications.

• Patients of childbearing potential not willing to use effective means of contraception.

• Positive HIV serology.

• Known addiction to alcohol or other drugs.

• Patients included in other clinical trial

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Adenocarcinoma
• Colorectal Neoplasms
• Metastatic Colorectal Cancer

Intervention

Drug:
• bevacizumab, capecitabine, oxaliplatin
6 cycles (3 weeks each one) of: bevacizumab: 7,5 mg/kg (iv), 1st day of each cycle. capecitabine: 1000 mg/m2 bid, oral. Days: 1-14 every three weeks. oxaliplatin: 130/mg/m2(iv),1st day of each cycle. After the first 6 cycles of treatment, continuing only with bevacizumab and capecitabine

Locations

Country	Name	City	State
Spain	Hospital Clinic i Provincial	Barcelona
Spain	Hospital General Yagüe	Burgos
Spain	Hospital de L´Hospitalet	Hospitalet de Llobregat	Barcelona
Spain	Hospital Lluis Alcanyis	Játiva	Valencia
Spain	Hospital de Gran Canaria Doctor Negrin	Las Palmas de Gran Canaria	Las Palmas
Spain	Hospital Arnau de Vilanova	Lérida
Spain	Hospital Quirón de Madrid	Madrid
Spain	Hospital Universitario la Paz	Madrid
Spain	Hospital Morales Meseguer	Murcia
Spain	Hospital de Navarra	Pamplona	Navarra
Spain	Hospital Infanta Sofía	San Sebastián de los Reyes	Madrid
Spain	Hospital Doctor Peset	Valencia
Spain	Hospital General de Valencia	Valencia
Spain	Hospital La Fe de Valencia	Valencia
Spain	Hospital Xeral Cies de Vigo	Vigo

Sponsors (1)

Lead Sponsor	Collaborator
Grupo Espanol Multidisciplinario del Cancer Digestivo

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to progression		3 years	No
Secondary	Overall survival		3 years	No
Secondary	Objective response rate following Response Evaluation Criteria In Solid Tumors (RECIST) criteria		3 years	No
Secondary	Overall response rate		3 years	No
Secondary	Number of treatment cycles administered		3 years	No
Secondary	Number of patients who have required dose reductions of either drug		3 years	No
Secondary	Safety of treatment according to the number of adverse events reported		3 yeras	Yes